Tags

Type your tag names separated by a space and hit enter

Extending levodopa action: COMT inhibition.
Neurology. 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8.Neur

Abstract

Degradation of levodopa in the periphery is known to be associated with motor fluctuations and dyskinesia in Parkinson's disease (PD) patients. The enzyme catechol-O-methyltransferase (COMT) is responsible for much of this degradation. Therefore, inhibiting COMT activity is one method of extending the action of levodopa. The new nitrocatechol-type COMT inhibitors entacapone, nitecapone, and tolcapone inhibit COMT in the periphery; tolcapone also inhibits COMT activity centrally. COMT inhibitors increase patients' duration of response to levodopa and reduce response fluctuations. Administration may prolong levodopa-induced dyskinesia, but peak-dose dyskinesia does not appear to increase. To reduce dyskinesia, the total daily dose of levodopa can be reduced.

Authors+Show Affiliations

Department of Neurology, Hospital Universitario de Getafe, Madrid, Spain.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9633684

Citation

Martínez-Martín, P, and C F. O'Brien. "Extending Levodopa Action: COMT Inhibition." Neurology, vol. 50, no. 6 Suppl 6, 1998, pp. S27-32; discussion S44-8.
Martínez-Martín P, O'Brien CF. Extending levodopa action: COMT inhibition. Neurology. 1998;50(6 Suppl 6):S27-32; discussion S44-8.
Martínez-Martín, P., & O'Brien, C. F. (1998). Extending levodopa action: COMT inhibition. Neurology, 50(6 Suppl 6), S27-32; discussion S44-8.
Martínez-Martín P, O'Brien CF. Extending Levodopa Action: COMT Inhibition. Neurology. 1998;50(6 Suppl 6):S27-32; discussion S44-8. PubMed PMID: 9633684.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Extending levodopa action: COMT inhibition. AU - Martínez-Martín,P, AU - O'Brien,C F, PY - 1998/6/20/pubmed PY - 1998/6/20/medline PY - 1998/6/20/entrez SP - S27-32; discussion S44-8 JF - Neurology JO - Neurology VL - 50 IS - 6 Suppl 6 N2 - Degradation of levodopa in the periphery is known to be associated with motor fluctuations and dyskinesia in Parkinson's disease (PD) patients. The enzyme catechol-O-methyltransferase (COMT) is responsible for much of this degradation. Therefore, inhibiting COMT activity is one method of extending the action of levodopa. The new nitrocatechol-type COMT inhibitors entacapone, nitecapone, and tolcapone inhibit COMT in the periphery; tolcapone also inhibits COMT activity centrally. COMT inhibitors increase patients' duration of response to levodopa and reduce response fluctuations. Administration may prolong levodopa-induced dyskinesia, but peak-dose dyskinesia does not appear to increase. To reduce dyskinesia, the total daily dose of levodopa can be reduced. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/9633684/Extending_levodopa_action:_COMT_inhibition_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=9633684.ui DB - PRIME DP - Unbound Medicine ER -